Key differences between anti-PD-1/PD-L1 inhibitors
Indications to immunotherapy in cancer treatment continue to expand, thus there are more and more questions about clinical aspects of using different checkpoint inhibitors. Despite similar mechanism of action between widely used antibodies to PD-1 (nivolumab, pembrolizumab, prolgolimab) and PD-L1 (...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Russo |
| Publicado em: |
Remedium Group LLC
2022-06-01
|
| Colecção: | Медицинский совет |
| Assuntos: | |
| Acesso em linha: | https://www.med-sovet.pro/jour/article/view/6911 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|